Stock Evaluator: TransMedics Group, Inc. (TMDX)

TransMedics Group, Inc. TMDX

$86.66 -0.90 -1.03%
September 17, 2026 4:00:00 PM EST November 10, 2021 Volume: 690,564
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics TMDX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3,004.9 $366.1 60%
Shares Out (Mil) 40.7 40.8 43%
Institutional Ownership 97.0% 83.3% 72%
Float (Mil) 33.6 35.1 38%
Beta 1.88 0.87 90%
Avg Daily Volume (000s) 726 299 66%
Price Change
(52-week)
(27.3%) 63.3% 28%
Growth TMDX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 88.3% 11.8% 98%
Net Income (5yr) 53.9% (5.7%) 95%
EPS (5yr) 44.0% 10.2% 90
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 90.0% (15.5%) 98%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 8 9 9
Current EPS $0.292 $1.542 $2.306
Month Ago EPS $0.299 $1.559 $2.306
# Rev Up 0 1 0
# Rev Down 2 1 1
Three Months Ago EPS $0.453 $2.046 $3.297
Year/Year Chg (28.1%) (68.4%) (32.3%)
Financials TMDX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $669 $119 44%
Net Income (TTM) (Mil) $152 ($9) 65%
EPS (TTM) $4.419 ($0.400) 84%
Operating Cash Flow (TTM) (Mil) $146 ($3) 55%
Net Cash Flow (TTM) (Mil) $90 $1 76%
Long-Term Debt (Q1) (Mil) $844 $23 64%
Enterprise Value (Q1) (Mil) $3,413 $376 56%
Valuation TMDX Industry
Median
Percentile
(All Stocks)
P/B 5.79 2.80 82%
P/E 21.6 25.7 57%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.5 1.4 24%
Ratios TMDX Industry
Median
Percentile
(All Stocks)
Gross Margin 58.7% 58.5% 71%
Net Margin 22.7% (6.9%) 81%
ROA 12.9% (12.3%) 91%
ROE 36.3% (11.1%) 90%
Liabilities to Assets 64.6% 46.6% 59%
F-Score 3 4 18%

TransMedics Group, Inc. did not pass any screens on 9/17/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors